BSE Live
Dec 30, 16:01Prev. Close
2006.90
Open Price
2009.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 30, 15:57Prev. Close
2009.70
Open Price
2004.60
Bid Price (Qty.)
2029.80 (78)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Glenmark Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 27.50 | 32.78 | 28.49 | 39.29 | 26.47 | |
| Diluted EPS (Rs.) | 27.50 | 32.78 | 28.49 | 39.28 | 26.46 | |
| Cash EPS (Rs.) | 42.28 | 44.33 | 39.19 | 48.66 | 34.64 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 215.12 | 198.63 | 182.98 | 159.20 | 128.63 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 215.12 | 198.63 | 182.98 | 159.20 | 128.63 | |
| Revenue from Operations/Share (Rs.) | 377.11 | 349.63 | 321.59 | 321.77 | 267.99 | |
| PBDIT/Share (Rs.) | 65.84 | 63.58 | 60.49 | 73.50 | 51.64 | |
| PBIT/Share (Rs.) | 51.05 | 52.03 | 49.79 | 64.13 | 43.34 | |
| PBT/Share (Rs.) | 38.84 | 46.09 | 39.67 | 52.86 | 37.00 | |
| Net Profit/Share (Rs.) | 27.50 | 32.78 | 28.49 | 39.29 | 26.33 | |
| NP After MI And SOA / Share (Rs.) | 27.50 | 32.78 | 28.49 | 39.29 | 26.33 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 17.45 | 18.18 | 18.80 | 22.84 | 19.27 | |
| PBIT Margin (%) | 13.53 | 14.88 | 15.48 | 19.93 | 16.17 | |
| PBT Margin (%) | 10.30 | 13.18 | 12.33 | 16.42 | 13.80 | |
| Net Profit Margin (%) | 7.29 | 9.37 | 8.85 | 12.21 | 9.82 | |
| NP After MI And SOA Margin (%) | 7.29 | 9.37 | 8.85 | 12.21 | 9.82 | |
| Return on Networth/Equity (%) | 12.78 | 16.50 | 15.56 | 24.67 | 20.47 | |
| Return on Capital Employed (%) | 13.64 | 15.82 | 15.09 | 19.97 | 11.99 | |
| Return on Assets (%) | 5.28 | 6.95 | 6.38 | 9.42 | 7.28 | |
| Total Debt/Equity (X) | 0.74 | 0.69 | 0.86 | 1.05 | 0.90 | |
| Asset Turnover Ratio (%) | 72.46 | 74.20 | 72.04 | 77.18 | 74.18 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.65 | 1.67 | 2.13 | 2.54 | 1.48 | |
| Quick Ratio (X) | 1.13 | 1.11 | 1.51 | 1.75 | 1.08 | |
| Inventory Turnover Ratio (X) | 4.98 | 4.38 | 4.47 | 4.24 | 4.82 | |
| Dividend Payout Ratio (NP) (%) | 8.76 | 7.35 | 8.44 | 6.12 | 9.14 | |
| Dividend Payout Ratio (CP) (%) | 5.70 | 5.43 | 6.14 | 4.94 | 6.94 | |
| Earnings Retention Ratio (%) | 91.24 | 92.65 | 91.56 | 93.88 | 90.86 | |
| Cash Earnings Retention Ratio (%) | 94.30 | 94.57 | 93.86 | 95.06 | 93.06 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 3.82 | 4.39 | 4.92 | 7.63 | 6.84 | |
| Interest Coverage Ratios (Post Tax) (%) | 3.82 | 4.39 | 4.92 | 7.63 | 6.84 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 9,188.07 | 21,154.12 | 18,076.35 | 27,868.58 | 24,829.26 | |
| EV/Net Operating Revenue (X) | 0.86 | 2.14 | 1.99 | 3.07 | 3.28 | |
| EV/EBITDA (X) | 4.95 | 11.79 | 10.59 | 13.44 | 17.04 | |
| MarketCap/Net Operating Revenue (X) | 0.55 | 1.85 | 1.64 | 2.67 | 2.96 | |
| Retention Ratios (%) | 91.23 | 92.64 | 91.55 | 93.87 | 90.85 | |
| Price/BV (X) | 0.96 | 3.25 | 2.88 | 5.39 | 6.17 | |
| Price/Net Operating Revenue | 0.55 | 1.85 | 1.64 | 2.67 | 2.96 | |
| Earnings Yield | 0.13 | 0.05 | 0.05 | 0.05 | 0.03 |
23.12.2025
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
03.12.2025
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015